Journal of Hepatology
Volume 51, Issue 4 , Pages 675-681 , October 2009

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

  • Calogero Cammà

      Affiliations

    • Cattedra di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
    • Institute of Biomedicine and Molecular Immunology, CNR Palermo, Palermo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 091 6552145; fax: +39 091 6552156.
    • ,
  • Giuseppe Cabibbo

      Affiliations

    • Cattedra di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
    • Dipartimento di Biopatologia e Metodologie Biomediche, University of Palermo, Palermo, Italy
    • ,
  • Fabrizio Bronte

      Affiliations

    • Cattedra di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
    • ,
  • Marco Enea

      Affiliations

    • Dipartimento di Scienze Statistiche e Matematiche, “S. Vianelli”, University of Palermo, Palermo, Italy
    • ,
  • Anna Licata

      Affiliations

    • Cattedra di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
    • ,
  • Massimo Attanasio

      Affiliations

    • Dipartimento di Scienze Statistiche e Matematiche, “S. Vianelli”, University of Palermo, Palermo, Italy
    • ,
  • Angelo Andriulli

      Affiliations

    • Divisione di Gastroenterologia, Casa Sollievo della Sofferenza, IRCCS Hospital San Giovanni Rotondo, San Giovanni Rotondo, FG, Italy
    • ,
  • Antonio Craxì

      Affiliations

    • Cattedra di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy

Received 9 April 2009 ,Revised 19 June 2009 ,Accepted 22 June 2009.

References 

  1. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  2. Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593–602
  3. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126:1015–1023
  4. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol. 2005;43:243–249
  5. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005;100:2453–2462
  6. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology. 2006;130:1098–1106
  7. Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci. 2006;51:1956–1961
  8. Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, et al. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, non-responders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis. 2006;10:11–16
  9. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006;55:1631–1638
  10. Ciancio A, Picciotto A, Giordanino C, Smedile A, Tabone M, Manca A, et al. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther. 2006;24:1079–1086
  11. Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol. 2006;44:484–490
  12. Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol. 2007;46:596–604
  13. Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM, et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther. 2007;26:1131–1138
  14. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option?. Dig Dis Sci. 2007;52:732–736
  15. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon-alfa/ribavirin therapy. Gastroenterology. 2009;136:1618–1628
  16. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009;150:528–540
  17. Gitlin N, Muther KD. Sustained viral response (SVR) with Peginterferon alfa-2 a and ribavirin in patients with chronic hepatitis C (CHC) who were non responders (NR) to Peginterferon alfa-2b and ribavirin. Hepatology. 2004;40(Suppl 1):343A
  18. Gaglio P, Choi J. Weight based ribavirin in combination with Pegylated interferon alpha 2-b does not improve SVR in HCV infected patients who failed prior therapy: results in 454 patients. Hepatology. 2005;42(Suppl 1):219A
  19. Gross JB, Stephanie M. Double-dose Peginterferon alfa-2b plus weight-based ribavirin for re-treatment of African-American nonresponders with hepatitis C. Gastroenterology. 2003;128(Suppl 1):684A
  20. Lawitz EJ, Bala NS. Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology. 2003;124(Suppl 1):783A
  21. Teuber G, Kallinowski B. Retreatment with Pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. Gastroenterology. 2003;124(Suppl 1):768A
  22. White C, Wentworth C. The target trial:final results using 3.0μG/Kg Pegylated interferon alfa 2-B (PEG; PEG-INTRON®) plu ribavirin (RBV; REBETOL®) for chronic hepatitis C patients who were nonresponders (NR) and relapsers (R) to previous therapy. Hepatology. 2005;42(Suppl 1):651A
  23. Strader DB, Wright T, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  24. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896–1900
  25. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  26. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2008;15:475–481

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00457-7

doi: 10.1016/j.jhep.2009.06.018

Journal of Hepatology
Volume 51, Issue 4 , Pages 675-681 , October 2009

Article Tools

* Image Usage & Resolution